PSYENCE BIOMEDICAL LTD.(PBM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PBM Stock Analysis & AI Quality Score
AI stock analysis and institutional research for PSYENCE BIOMEDICAL LTD. (PBM), a Healthcare sector company. PBM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Top institutional holders of PBM by reported 13-F value include Parallel Advisors,, Harraden Circle Investments,, Polar Asset Management Partners, based on the most recent SEC filings. PBM trades on the Nasdaq exchange and files with the SEC under CIK 1985062. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PSYENCE BIOMEDICAL LTD. directly from SEC EDGAR.
AI Insight: PBM Financial Trends
Insufficient financial data to assess trends — all key metrics absent across four quarters.
• No revenue, net income, operating income, cash flow, debt, or equity figures available for any quarter Q1 2024–Q3 2025.
⚠ Data gaps prevent assessment of profitability, cash generation, leverage, and balance sheet health.
AI Insight: PBM Ratio Trends
Insufficient financial data to assess trends; all key profitability and efficiency ratios are missing across the period.
• No operational margin, net profit margin, ROE, ROA, ROIC, or leverage data available for any period Q1 2024–Q3 2025.
⚠ Complete absence of financial metrics prevents assessment of profitability, capital efficiency, and balance sheet health.
Get alerted when PBM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PSYENCE BIOMEDICAL LTD. including:
Top Institutional Holders of PBM
Parallel Advisors, LLC
$574.8K151,250 shHarraden Circle Investments, LLC
$20.9K1,150,000 shPolar Asset Management Partners Inc.
$13.3K733,000 shMMCAP International Inc. SPC
$10.9K600,000 shTORONTO DOMINION BANK
$9.1K503,312 shCalamos Advisors LLC
$9.1K500,000 shSaba Capital Management, L.P.
$5.4K297,847 shClear Street Group Inc.
$4.7K257,209 shARISTEIA CAPITAL, L.L.C.
$3.9K215,319 shGOLDMAN SACHS GROUP INC
$3.6K200,117 sh
| Fund | Value | Shares |
|---|---|---|
| Parallel Advisors, LLC | $574.8K | 151,250 |
| Harraden Circle Investments, LLC | $20.9K | 1,150,000 |
| Polar Asset Management Partners Inc. | $13.3K | 733,000 |
| MMCAP International Inc. SPC | $10.9K | 600,000 |
| TORONTO DOMINION BANK | $9.1K | 503,312 |
| Calamos Advisors LLC | $9.1K | 500,000 |
| Saba Capital Management, L.P. | $5.4K | 297,847 |
| Clear Street Group Inc. | $4.7K | 257,209 |
| ARISTEIA CAPITAL, L.L.C. | $3.9K | 215,319 |
| GOLDMAN SACHS GROUP INC | $3.6K | 200,117 |
More Healthcare Companies
View all Healthcare →Put PBM on your watchlist
Track score changes the day PSYENCE BIOMEDICAL LTD. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PBM a good stock to buy?
13F Pro's AI-powered analysis of PSYENCE BIOMEDICAL LTD. (PBM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PBM are available on the PBM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PBM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PBM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PSYENCE BIOMEDICAL LTD.'s investment landscape.